

HYPOTHESIS

Open Access



Epitranscriptomics and epigenetics: two sides of the same coin?

Guglielmo Bove¹, Nunzio Del Gaudio^{1*} and Lucia Altucci^{1,2,3*}

Abstract

Gene expression is an intricate biological process that bridges gap between the genotype and the phenotype. Canonical and heritable epigenetic mechanisms, such as histone and DNA modifications, regulate the release of genetic information encoded in DNA without altering the underlying sequence. Many other non-canonical players, such as chromatin regulators and noncoding RNAs, are also involved in regulating gene expression. Recently, RNA modifications (epitranscriptomics) have been shown to hold enormous potential in shaping cellular transcriptomes. However, their co-transcriptional nature and uncertain heritability mean that they fall outside the current definition of epigenetics, sparking an ongoing debate in the field. Here we will discuss the relationship between canonical and non-canonical epigenetic mechanisms that govern gene expression and offer our perspective on whether (or not) epitranscriptomic modifications can be classified as epigenetic mechanisms.

Keywords Epigenetics, Epitranscriptomics, Methylation, DNA, RNA, Epigenetic memory

Main text

Unraveling the mechanisms by which genetic variation translates into phenotypic diversity at the cell, tissue, or organism level has long remained a major challenge in biology. Initially, genetic mutations were considered the exclusive source of trait diversity. However, examples of phenotypic variability in cells and humans bearing the same genetic code (e.g., cell differentiation and homozygous twins) called this idea into question. In 1942, the developmental biologist C. H. Waddington inferred the existence of mechanisms that act “on top of” (hence the prefix “epi” from Greek) genetics, defining epigenetics as “the branch of biology which studies the causal

interactions between genes and their products, which bring the phenotype into being” (Waddington, 1942). Over time, the concept of epigenetics has broadened, moving beyond developmental and evolutionary biology to encompass all chromatin-associated (heritable) mechanisms that regulate gene expression without altering the DNA sequence. According to this definition, deposition of 5-methylcytosine (5mC) at gene promoters and histone post-translational modifications (hPTMs) were recognized among the first examples of epigenetic traits (reviewed in [1]). Subsequently, the discovery of other mechanisms influencing the cellular transcriptome beyond chromatin regulation has increased the complexity of the epigenetic landscape. For instance, the existence of topology-associated domains that drive gene expression through inter- and intra-chromatinic interactions and the presence of noncoding RNAs, such as microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA) that participate in the transduction of genetic information by either sponging, scaffolding, or localizing transcripts, are all examples of newly epimechanisms influencing gene expression beyond genomic changes (reviewed in [1]). More recently, RNA

*Correspondence:

Nunzio Del Gaudio
nunzio.delgaudio@unicampania.it
Lucia Altucci
lucia.altucci@unicampania.it

¹ Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Vico L. de Crecchio 7, Naples, Italy

² BIOGEM, Via Camporeale, Ariano Irpino, Italy

³ UP Medical Epigenetics, AOU Vanvitelli, Naples, Italy



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

modifications have added a further layer of complexity to link the “epigenotype” with the specific phenotype.

Epitranscriptomic modifications, such as 5mC, 7-methyl-guanine (m7G), and pseudouridine, control the fate of thousands of RNAs, and their deposition is dynamically regulated by various effectors, including writers, erasers, and readers (reviewed in [2]).

Among the several modifications N^6 -methyladenosine (m^6A) is the most abundant and widespread epimark on RNA molecules, and it governs multiple steps of RNA metabolism by regulating the processing, stability, and translation of RNAs in nearly every biological process, ultimately affecting gene expression post-transcriptionally (reviewed in [3]). Since the current definition of epigenetics primarily focuses on the various mechanisms that regulate gene expression without altering the DNA sequence, the question arises as to whether epitranscriptomics can be considered a part of epigenetics. We believe that the answer to this controversy hinges on the definition of epigenetics, with a key point being the heritability of epigenetic memory. Typically, transgenerational epigenetic inheritance (TEI) involves the propagation of epigenetic traits across generations in the absence of continuous environmental cues. Although TEI is widely recognized in plants, fungi, and worms (reviewed in [4]), its existence in animals remains uncertain. In mammals, the transmission of DNA methylation at CpG islands (e.g., 5mC) and hPTMs through TEI has been proposed. Recently, *de novo* methylation of CpG-free DNA introduced by the transposase technology at the *Ankrd26* promoter was found to generate an obese phenotype that was maintained over multiple mice generations, showing that metabolic phenotypes associated with a specific DNA methylation signature are inherited *in vivo* [5]. Propagation of hPTM information was also confirmed *in vitro*. The deregulation of mini-chromosome maintenance complex component 2, a DNA helicase responsible for correct histone segregation and hPTM transmission, was shown to induce aberrant inheritance of histone methylation marks that impaired embryonic cell differentiation [6]. Therefore, evidence of the potential transmissibility of 5mC and hPTMs, together with their influence on cell transcription, supports their inclusion in the definition of epigenetics. Conversely, the transmissibility of RNA-based epitranscriptomics is more controversial. Intriguingly, the injection of RNAs (e.g., miRNAs, transfer RNA (tRNA)-derived small RNAs) into mice sperm or transfer RNA fragments (tRNA) into fertilized eggs was sufficient to reproduce and propagate parental phenotypes, such as white-tail color, metabolic defects due to high-fat diet, mice gigantism, and stress behavior (reviewed in [7]). RNA marks have also been proposed to participate in TEI. Cytosine methylation of tRNAs in mice sperm by

DNA methyltransferase 2 (DNMT2) was found essential for the induction and propagation of the white-tail and hypertrophic phenotypes in mice [8]. Similarly, TEI of susceptibility to seminomas was increased in mice with reduced cytosine deamination due to the loss of the RNA modifier apolipoprotein B catalytic polypeptide 1 (APOBEC1) [9]. Together, these findings highlight the fact that sperm RNAs, and their related modifications, may act as potential carriers of epimemory. Concerning m^6A , although numerous studies have highlighted its crucial role in meiosis and embryonic development, a precise mechanism has not yet been proposed. Interestingly, maternal inheritance of m^6A marks was recently reported in mice embryos, where the presence of m^6A on a subset of maternally transmitted transcripts was correlated to the enhancement of their translation [10]. However, the high dynamism and likely stability of RNA modifications and DNA marks (such as hPTMs and CpG methylation) still leaves many questions unanswered as to how the epitranscriptomic signature may be transmitted to offspring.

Signatures of the RNA modifications 5mC and 2-methyl-guanine (m2G) were found altered in high-fat diet mice progeny, and their aberrant deposition, in combination with tRNAs, DNA methylation, and hPTMs, was proposed to mediate the acquired metabolic phenotype in mice [11]. These findings suggest that the transmission of epitranscriptomics is a multifactorial event, likely driven by multiple epigenetic layers rather than a single epigenetic cue. Thus, limiting the concept of epigenetics to inheritance and gene expression ignores the dynamic interplay of pathways acting on chromatin (epigenetics), RNA (epitranscriptomics), and proteins (epiproteomics). These pathways work together “on top of” the resulting phenotype. Expanding on the original definition of epigenetics by Waddington, we are convinced that epigenetics, epitranscriptomics, and epiproteomics are strongly interconnected in a “cell epiregulation” network that defines the cellular gene function output and fosters phenotypic variability (Fig. 1). For example, the fact that cellular methyltransferases, despite targeting different substrates (DNA, RNA, and histones), all use *S*-adenosyl methionine (SAM) as the methyl donor, hints at the existence of a common regulatory network. According to this model, multiple layers of regulation such as (i) mechanisms acting at DNA level (e.g., 5mC and hPTMs) that influence transcription initiation, (ii) noncoding RNA species and RNA marks governing stability, abundance, and functionality of transcripts, (iii) chromatin tridimensional organization in TADs, and (vi) post-translational modifications that regulate protein activity, all cooperate to define cellular gene activity (Fig. 1). Epitranscriptomics can therefore (and for the time being) be considered part

Epi-Regulation




Fig. 1 Epiregulation: Unified view of interconnected epigenetic, epitranscriptomic, and epiproteomic mechanisms that shape gene activity and cell phenotype. **(1)** Mechanisms acting at DNA level (e.g., 5mC and hPTMs) that influence transcription initiation. **(2)** RNA marks governing the stability, abundance, and functionality of transcripts. **(3)** PTM versus hPTM that regulate protein activity

of the “cell epiregulation” system, which also includes epigenetics and epiproteomics. In line with this view, epiregulation is the blueprint of gene activity, and its interconnected branches (i.e., epigenetics, epitranscriptomics, and epiproteomics) only represent the layers and substrates on which epiregulation acts. Examples of transcriptional interplay such as the functional interaction of epitranscriptomic factors with histone marks (e.g., METTL14 binding H3K36me3) [12], the spread of Polycomb repressive complexes (PRC) on chromatin by lncRNAs [13], the influence of m⁶A on miRNA biogenesis, and crosstalk between different hPTMs, different RNA

marks, and each other (reviewed in [14]) indicate that we cannot consider these mechanisms distinct. Instead, they are tightly interconnected as part of one unique process (epiregulation) in which they intersect to define gene activity and ultimately shape the cell phenotype.

At this point, the question again arises: is epitranscriptomics epigenetics?

Considering the substrate “on top of” which they act, we cannot recognize epitranscriptomics as epigenetics. However, considering the effects “on top of” the phenotype that are determined by gene activity, we can assert that epitranscriptomics, epigenetics and epiproteomics

are two sides of the same coin, both participating in a complex network of interconnections that we define “cell epiregulation.”

This concept is supported and strengthened by the immense clinical implications both as epibiomarkers of human diseases (but not restricted to) such as cancer and as therapeutic opportunities. Undoubtedly the next future also with the availability of always more defined technologies will clarify further the deep epi-interplay that shapes the normal and the pathological phenotype and its heritability.

Abbreviations

m2G	2-Methyl-guanine
5mC	5-Methylcytosine
APOBEC1	Apolipoprotein B catalytic polypeptide 1
circRNA	Circular RNA
DNMT2	DNA methyltransferase 2
hPTMs	Histone post-translational modifications
lncRNA	Long non-coding RNA
miRNA	MicroRNA
m ⁶ A	N ⁶ -methyladenosine
ncRNAs	Non-coding RNAs
PRC	Polycomb repressive complexes
SAM	S-adenosyl methionine
tsRNA	TRNA-derived small RNAs
TADs	Topology-associated domains
tRNA	Transfer RNA fragments
TEI	Transgenerational epigenetic inheritance

Acknowledgements

We thank C. Fisher for linguistic editing.

Author contributions

Project administration and supervision: N.D.G., G.B., and L.A.; conceptualization and writing: N.D.G. and G.B.; review and editing: L.A. All the authors read and approved the final manuscript.

Funding

This work was supported by PNRR-MAD-2022-12376723; PNRR-CN3, National Centre for Gene Therapy and Drugs Based on RNA Technology, cod: CN000000041. NextGenerationEU—CUP: B83C22004960002. EPI-MET Fondo Crescita Sostenibile—Accordi per l'Innovazione D.M. 31.12.2021, D.D. 18.03.2022 no. 34; project no. F/310034/03/X56 (VANVITELLI). PRIN P2022F3YRF; Bando di Ateneo per il finanziamento di progetti di ricerca fondamentale ed applicata dedicato ai giovani ricercatori D.R. no. 834 of 30/09/2022: IDEA (CUP: B63C22001470005). VALERE: Vanvitelli per la Ricerca Program: EPInhibitDRUGre (CUP: B66J20000680005). N.D.G. was supported by PON Ricerca e Innovazione 2014–2020.

Availability of data and materials

No datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 30 July 2024 Accepted: 12 August 2024

Published online: 03 September 2024

References

- Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. *Nat Rev Genet.* 2016;17(8):487–500.
- Delaunay S, Helm M, Frye M. RNA modifications in physiology and disease: towards clinical applications. *Nat Rev Genet.* 2024;25(2):104–22.
- Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. *Mol Cell.* 2023;83(3):428–41.
- Bošković A, Rando OJ. Transgenerational epigenetic inheritance. *Annu Rev Genet.* 2018;52:21–41.
- Takahashi Y, Morales Valencia M, Yu Y, Ouchi Y, Takahashi K, Shokhirev MN, et al. Transgenerational inheritance of acquired epigenetic signatures at CpG islands in mice. *Cell.* 2023;186(4):715–31.e19.
- Wenger A, Biran A, Alcaraz N, Redó-Riveiro A, Sell AC, Krautz R, et al. Symmetric inheritance of parental histones governs epigenome maintenance and embryonic stem cell identity. *Nat Genet.* 2023;55(9):1567–78.
- Boscardin C, Manuella F, Mansuy IM. Paternal transmission of behavioural and metabolic traits induced by postnatal stress to the 5th generation in mice. *Environ Epigenet.* 2022;8(1):dvac024.
- Kiani J, Grandjean V, Liebers R, Tuorto F, Ghanbarian H, Lyko F, et al. RNA-mediated epigenetic heredity requires the cytosine methyltransferase Dnmt2. *PLoS Genet.* 2013;9(5):e1003498.
- Nelson VR, Heaney JD, Tesar PJ, Davidson NO, Nadeau JH. Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability. *Proc Natl Acad Sci USA.* 2012;109(41):E2766–73.
- Zhu W, Ding Y, Meng J, Gu L, Liu W, Li L, et al. Reading and writing of mRNA m(6)A modification orchestrate maternal-to-zygotic transition in mice. *Genome Biol.* 2023;24(1):67.
- Chen Q, Yan M, Cao Z, Li X, Zhang Y, Shi J, et al. Sperm tsRNAs contribute to intergenerational inheritance of an acquired metabolic disorder. *Science (New York, NY).* 2016;351(6271):397–400.
- Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, et al. Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally. *Nature.* 2019;567(7748):414–9.
- Schertzer MD, Bracerros KCA, Starmer J, Cherney RE, Lee DM, Salazar G, et al. lncRNA-Induced spread of polycomb controlled by genome architecture, RNA abundance, and CpG Island DNA. *Mol Cell.* 2019;75(3):523–37.e10.
- Fico A, Di Croce L, Matarazzo MR. Interplay between DNA and RNA modifications: a constantly evolving process. *Epigenomes.* 2020;4(4):26.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.